Modus Therapeutics pauses enrollment in Phase IIa sevuparin trial after serious adverse event
Bitget2026/10/14 18:35- Modus Therapeutics voluntarily paused enrollment in Part 2 of its Phase IIa sevuparin trial for chronic kidney disease with anemia.
- A serious adverse event prompted the precautionary pause; a causal link to sevuparin has not been established.
- The pause was not regulator-imposed; no ongoing patient treatment required discontinuation.
- Proof-of-concept results are now expected in the first quarter of 2027, versus around the turn of 2026/2027 previously.
- Cash is expected to fund operations into the second quarter of 2027; an updated financing assessment is due November 24, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.
Why Nintendo Stock Is One to Watch Ahead of the Holiday Season
A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.
Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.
Crypto prices
More
